Skip to NavigationSkip to content

New Phase 3 data confirms safety and efficacy of UCB's Cimzia in plaque and psoriatic arthritis

Published on 30/04/19 at 10:32am

New Phase 3 data has been released by UCB Pharma on the safety of Cimzia (certolizumab pegol) in the treatment of moderate-to-severe plaque psoriasis, and its efficacy in patients showing signs of psoriasis-related nail disease and those showed an inadequate early treatment response to the drug.

The first 96 weeks of data derived from 995 participants across two ongoing Phase 3 studies demonstrated that “confirmed the long-term safety of Cimzia in the treatment of psoriasis”, with no new safety concerns flagged, while the overall incidence of adverse events was low.

Additionally, pooled 48-week data from the two studies showed that 66% of psoriasis patients with nail disease achieved total resolution, with results consistent on either regimen and with similar efficacy in patients with and without concomitant psoriatic arthritis.

The data also demonstrated that, in patients who responded partially or inadequately in the first 16 weeks of treatment, Cimzia produced an improvement in PASI75, PASI90 and PGA 0/1 response rates over an additional 32 weeks of treatment with 400mg every two weeks.

“This new research demonstrates UCB’s ongoing commitment to delivering meaningful outcomes for psoriasis patients, where there is still significant unmet need,” said Emmanuel Caeymaex, Head of Immunology and Executive Vice President at UCB. “This includes patients with psoriatic nail disease and those who do not initially adequately respond to their treatment dose. The multitude of evidence from these ongoing trials complements data from across all areas of chronic inflammatory diseases to show the value of Cimzia in treating different patient populations.”

Matt Fellows

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches